News | December 16, 2014

3-D Brain SPECT Helps Diagnose ADHD

Findings indicate that stronger signal is obtained when 3-D thresholded SPECT scan is performed rather than conventional SPECT scan; similar results may be obtained for other psychiatric disorders

Nuclear imaging, Clinical trial/study, ADHA, 3-D SPECT imaging

December 16, 2014 — A recently published study from Toronto, Canada found that patients who utilized 3-D SPECT were able to get a clearer diagnosis of ADHD, which is the most common psychiatric disorder in children and adults.

Published in the Journal of Neuropsychiatry and Clinical Neurosciences, the study used 3-D SPECT imaging, a nuclear medicine study that evaluates blood flow and activity levels in the brain. This research demonstrated that 3-D SPECT imaging is a beneficial tool for ruling in or out ADHD.

This study is important because of the way the SPECT scans were rendered. The 3-D renderings made the scans easier to read than the typical 2-D images, which required greater reading skills of the physicians. In the present study, 3-D thresholded SPECT scans gave a sensitivity of 83% in predicting which patients would have a clinical diagnosis of ADHD compared with a sensitivity of 10% for the conventional 2-D SPECT scans. A 10% sensitivity hardly makes SPECT scans useful for clinical psychiatric applications, which is why some researchers have criticized the use of traditional SPECT.

Daniel G. Amen, M.D., psychiatrist and founder of Amen Clinics, who is referenced in the published article but did not participate in this particular study, says, "This study points to a significant advancement in the care of people who suffer with ADHD and other psychiatric disorders. Until now, standard diagnoses in psychiatry are made primarily through talking to patients and looking at symptom clusters without any biological information. Psychiatry is the only medical specialty that virtually never looks at the organ it treats.”

For more information: www.neuro.psychiatryonline.org/doi/abs/10.1176/appi.neuropsych.12110280

 

Related Content

Study Explores Magnetic Nanoparticles as Bimodal Imaging Agent for PET/MRI

Image courtesy of MR Solutions.

News | PET-MRI | May 23, 2019
Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (...
Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
VolparaDensity With Tyrer-Cuzick Model Improves Breast Cancer Risk Stratification
News | Breast Density | May 22, 2019
Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
AI Detects Unsuspected Lung Cancer in Radiology Reports, Augments Clinical Follow-up
News | Artificial Intelligence | May 20, 2019
Digital Reasoning announced results from its automated radiology report analytics research. In a series of experiments...
New Study Evaluates Head CT Examinations and Patient Complexity
News | Neuro Imaging | May 17, 2019
Computed tomography (CT) of the head uses special X-ray equipment to help assess head injuries, dizziness and other...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Managing Architectural Distortion on Mammography Based on MR Enhancement
News | Mammography | May 15, 2019
High negative predictive values (NPV) in mammography architectural distortion (AD) without ultrasonographic (US)...
Icon Launches New Clinical Trial Patient Engagement Platform
Technology | Patient Engagement | May 14, 2019
Icon plc announced the release of its web-based clinical trial patient engagement platform, to provide patients with...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...